Phase III results move Aimmune’s peanut allergy drug closer to EU market
admin 27th March 2019 Uncategorised 0Aimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance. More: Phase III results move Aimmune’s peanut allergy drug closer to EU market Source: News
read more